MedPath

Lisinopril

Generic Name
Lisinopril
Brand Names
Prinivil, Qbrelis, Zestoretic, Zestril
Drug Type
Small Molecule
Chemical Formula
C21H31N3O5
CAS Number
76547-98-3
Unique Ingredient Identifier
7Q3P4BS2FD
Background

Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction. Lisinopril and captopril are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.

Lisinopril was granted FDA approval on 29 December 1987.

Indication

Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure. A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.

Associated Conditions
Acute Myocardial Infarction (AMI), Cardiovascular Events, Congestive Heart Failure (CHF), Diabetic Nephropathy, Hypertension, Migraine

Women With Chest Pain and Normal Coronary Arteries Study

Not Applicable
Terminated
Conditions
Chest Pain
Interventions
Behavioral: Therapeutic Lifestyle Changes
First Posted Date
2008-08-28
Last Posted Date
2023-12-12
Lead Sponsor
Northwestern University
Target Recruit Count
3
Registration Number
NCT00743197
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

Black Education and Treatment of Hypertension (BEAT HTN)

First Posted Date
2008-04-21
Last Posted Date
2012-12-04
Lead Sponsor
Creighton University
Target Recruit Count
99
Registration Number
NCT00661895
Locations
🇺🇸

Creighton Community Health Center, Omaha, Nebraska, United States

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

Phase 3
Completed
Conditions
Hypertension
Interventions
First Posted Date
2008-02-26
Last Posted Date
2016-12-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
348
Registration Number
NCT00624065
Locations
🇺🇸

GSK Investigational Site, Beloit, Wisconsin, United States

The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial

Phase 2
Completed
Conditions
Cognitive Impairment
Hypertension
Aging
Interventions
Drug: nifedipine, long acting
Drug: metoprolol, long-acting
First Posted Date
2008-01-30
Last Posted Date
2013-02-15
Lead Sponsor
University of Southern California
Target Recruit Count
53
Registration Number
NCT00605072
Locations
🇺🇸

Hebrew SeniorLife, Boston, Massachusetts, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

Hypertension in Hemodialysis Patients (Aim 3)

Phase 3
Terminated
Conditions
Left Ventricular Hypertrophy
Hemodialysis
Hypertension
Interventions
First Posted Date
2007-12-28
Last Posted Date
2016-01-18
Lead Sponsor
Indiana University
Target Recruit Count
200
Registration Number
NCT00582114
Locations
🇺🇸

Indiana University, Indianapolis, Indiana, United States

VA NEPHRON-D: Diabetes iN Nephropathy Study

Phase 3
Terminated
Conditions
Kidney Disease
Nephropathy
Type 2 Diabetes
Interventions
First Posted Date
2007-11-08
Last Posted Date
2015-05-29
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
1448
Registration Number
NCT00555217
Locations
🇺🇸

VA Palo Alto Health Care System, Palo Alto, California, United States

🇵🇷

VA Medical Center, San Juan, San Juan, Puerto Rico

🇺🇸

VA Medical Center, Memphis, Memphis, Tennessee, United States

and more 28 locations

Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease

Phase 1
Completed
Conditions
Pre-hypertension
Interventions
First Posted Date
2007-11-06
Last Posted Date
2018-04-24
Lead Sponsor
University of Minnesota
Target Recruit Count
101
Registration Number
NCT00553969
Locations
🇺🇸

University of Minnesota, Variety Club Research Center 102, Minneapolis, Minnesota, United States

A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.

Phase 1
Completed
Conditions
Hypertension
First Posted Date
2007-11-02
Last Posted Date
2010-10-15
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
55
Registration Number
NCT00552708
Locations
🇺🇸

GSK Investigational Site, Tacoma, Washington, United States

Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives

Phase 1
Completed
Conditions
Hypertension
Interventions
First Posted Date
2007-07-30
Last Posted Date
2017-08-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
62
Registration Number
NCT00508365
Locations
🇺🇸

GSK Investigational Site, San Antonio, Texas, United States

The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients

Phase 3
Completed
Conditions
Abdominal Obesity
Hypertension
Interventions
First Posted Date
2007-04-11
Last Posted Date
2013-12-06
Lead Sponsor
St. Paul Heart Clinic
Target Recruit Count
25
Registration Number
NCT00459056
Locations
🇺🇸

St. Paul Heart Clinic, St. Paul, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath